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The patient, a 55-year-old man, had undergone surgery for retroperitoneal paraganglioma at the age of
45. In February 2006, he visited our hospital with the chief complaint of metastatic tumors detected by a
thorough checkup. Computed tomographic (CT) scan revealed a large tumor in the right kidney hilar
region and a left supraclavicular lymphadenopathy. Histopathological and immunohistochemical findings
of the biopsy specimen taken from the left supraclavicular lymph node led to the diagnosis of recurrent
malignant paraganglioma. 123I-MIBG scintigram showed no radioisotope accumulation consistent with the
tumor. From April 2006 to September 2006, he received 8 cycles of CVD therapy (cyclophosphamide,
vincristine, and dacarbazine). The tumor temporarily responded and was reduced to one-third in size, but
soon it became resistant to CVD therapy. In March 2007, because the tumor had begun to grow, he
received the 9th course of CVD therapy, but the tumor response was PD. Subsequently, palliative radiation
therapy of 50 Gy in 25 fractions was administered and was temporarily effective. The CVD therapy and
radiation therapy were considered to be effective for this case. In May 2008, he died 25 months after the
start of CVD therapy.
(Hinyokika Kiyo 55 : 691-694, 2009)















現病歴 : 1996年 6月，他院にて径 8 cm 大の後腹膜
腫瘍摘出術を施行され後腹膜 paraganglioma と診断さ
れた．2002年 9月まで経過観察されたが再発は指摘さ
れず，以降 follow-up されていなかった．2006年 2月，
検診にて右腎門部腫瘤，左鎖骨上窩リンパ節腫脹を指
摘され悪性リンパ腫疑われ当院血液内科紹介受診．左
鎖骨上窩リンパ節生検にて malignant paraganglioma の
リンパ節転移と診断され当科紹介，精査加療目的に入
院となった．






Table 1. Endocrinological findings on admission
Serum Adrenaline ＜0.01 ng/ml (0.01-0.17)
Noradrenaline 1.4 ng/ml (0.16-0.57)
Dopamine 0.43 ng/ml (0.01-0.03)
Urine VMA 16.1 mg/day (1.4 -4.9 )
Metanephrine 0.09 mg/day (0.04-0.19)
Normetanephrine 4.93 mg/day (0.09-0.33)
VMA, vanillylmandelic acid.











部は S-100 陽性であった (Fig. 2）．1996年の後腹膜腫
瘍摘出標本は破棄されており確認できなかった．
治療経過 : 以上から malignant paraganglioma 再発，
多発リンパ節転移と診断した．MIBG シンチグラフィ
で異常集積を認めないことからアイソトープ治療は
無効と考え，2006年 4 月より CVD 療法 (cyclopho-
sphamide 750 mg/m2 on day 1，vincristine 2.0 mg/body
on day 1，dacarbazine 600 mg/m2 on day 1 and 2，every
21 days) を開始した．1 course 目から縮小傾向がみら
れ，5 course 目終了時点でPR（67，76％の縮小率）を
得た (Fig. 1）．しかし 6 course 目以降は縮小傾向が認
められなくなり2006年 9月，8 course 目終了後に経過
観察となった．2007年 3月，腫瘤が増大してきたため




射線治療 (50 Gy/25 fr) を施行した．この際，腎門部
腫瘤も照射野に含めたところ縮小率76％を得た．同年
7月には，急速に増大する頸部リンパ節，左鎖骨上窩



















Fig. 1. (a, c) CT scans revealed a left supraclavicular lymphadenopathy and a solid tumor in the right kidney hilar
region before CVD therapy. (b, d) After 5 cycles of CVD therapy, tumors were reduced to one-third in
size.













Fig. 2. Histopathological and immunohistochemical findings of the biopsy specimen taken from the left
supraclavicular lymph node. (a) Chief cells were disposed in nests and surrounded by a single layer of
sustentacular cells. Chief cells were positive for (b) chromogranin A and (c) synaptophysin, and (d)
sustentacular cells were positive for S-100.
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Fig. 3. The tumors were reduced 67％ (a, b) and 76％ (c, d) respectively by radiation therapy.
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25 fr の線量が必要とする review があり，それらを参
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